Overexpression and pre-treatment of recombinant human Secretory Leukocyte Protease Inhibitor (rhSLPI) reduces an in vitro ischemia/reperfusion injury in rat cardiac myoblast (H9c2) cell

Overexpression and pre-treatment of recombinant human Secretory Leukocyte Protease Inhibitor (rhSLPI) reduces an in vitro ischemia/reperfusion injury in rat cardiac myoblast (H9c2) cell

One of the major causes of cardiac cell death during myocardial ischemia is the oversecretion of protease enzymes surrounding the ischemic tissue. Therefore, inhibition of the protease activity could be an alternative strategy for preventing the expansion of the injured area. In the present study, w...

Full description

Bibliographic Details
Main Authors: Prompunt Eakkapote, Nernpermpisooth Nitirut, Sanit Jantira, Kumphune Sarawut
Format: Article
Language:English
Published: De Gruyter 2018-05-01
Series:Biomolecular Concepts
Subjects:
myocardial ischemia
secretory leukocyte protease inhibitor (SLPI)
ischemia/reperfusion injury (I/R)
SLPI overexpression
p38 MAPK
Online Access:http://www.degruyter.com/view/j/bmc.2018.9.issue-1/bmc-2018-0004/bmc-2018-0004.xml?format=INT

Internet

http://www.degruyter.com/view/j/bmc.2018.9.issue-1/bmc-2018-0004/bmc-2018-0004.xml?format=INT

Similar Items